Fullard, M. E., Thibault, D. P., Hill, A., Fox, J., Bhatti, D. E., Burack, M. A., Dahodwala, N., Haberfeld, E., Kern, D. S., Klepitskava, O. S., Urrea-Mendoza, E., Myers, P., Nutt, J., Rafferty, M. R., Schwalb, J. M., Shulman, L. M., Willis, A. W., On behalf of the Parkinson Study Group Healthcare Outcomes and Disparities Working Group September 3, 2017

Objective:

To examine rehabilitation therapy utilization for Parkinson disease (PD).

Methods:

We identified 174,643 Medicare beneficiaries with a diagnosis of PD in 2007 and followed them through 2009. The main outcome measures were annual receipt of physical therapy (PT), occupational therapy (OT), or speech therapy (ST).… Read More...

Markus, H. S., Larsson, S. C., Kuker, W., Schulz, U. G., Ford, I., Rothwell, P. M., Clifton, A., For the VIST Investigators September 3, 2017

Objective:

To compare in the Vertebral Artery Ischaemia Stenting Trial (VIST) the risks and benefits of vertebral angioplasty and stenting with best medical treatment (BMT) alone for symptomatic vertebral artery stenosis.

Methods:

VIST was a prospective, randomized, open-blinded endpoint clinical trial performed in 14 hospitals in the United Kingdom.… Read More...

Rooney, J. P. K., Visser, A. E., D'Ovidio, F., Vermeulen, R., Beghi, E., Chio, A., Veldink, J. H., Logroscino, G., van den Berg, L. H., Hardiman, O., For the Euro-MOTOR Consortium September 3, 2017

Objective:

To investigate the role of hormonal risk factors for amyotrophic lateral sclerosis (ALS) among women from 3 European countries.

Methods:

ALS cases and matched controls were recruited over 4 years in Ireland, Italy, and the Netherlands. Hormonal exposures, including reproductive history, breastfeeding, contraceptive use, hormonal replacement therapy, and gynecologic surgical history, were recorded with a validated questionnaire.… Read More...

Godel, T., Bäumer, P., Pham, M., Köhn, A., Muschol, N., Kronlage, M., Kollmer, J., Heiland, S., Bendszus, M., Mautner, V.-F. September 3, 2017

Objective:

To evaluate functional and morphometric magnetic resonance neurography of the dorsal root ganglion and peripheral nerve segments in patients with Fabry painful neuropathy.

Methods:

In this prospective study, the lumbosacral dorsal root ganglia and proximal peripheral nerve segments of the lower extremity were examined in 11 male patients with Fabry disease by a standardized 3T magnetic resonance neurography protocol.… Read More...

Compter, A., Chaturvedi, S. September 3, 2017

Up to a quarter of patients with vertebrobasilar ischemic stroke or TIA have a symptomatic stenosis of the vertebrobasilar arteries.1,2 Patients with vertebral artery (VA) stenosis 50% have a high risk of recurrent stroke, comparable to patients with symptomatic carotid artery stenosis, with the highest risk during the first weeks after the initial TIA or ischemic stroke.… Read More...

Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., Margolin, D. H., Thangavelu, K., Chirieac, M. C., Jody, D., Xenopoulos, P., Hogan, R. J., Panzara, M. A., Arnold, D. L., On behalf of CARE-MS II and CAMMS03409 Investigators September 3, 2017

Objective:

To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy.

Methods:

In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtuzumab-treated patients received 2 courses (baseline and 12 months later).… Read More...

Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., Margolin, D. H., Thangavelu, K., Rodriguez, C. E., Jody, D., Hogan, R. J., Xenopoulos, P., Panzara, M. A., Coles, A. J., On behalf of CARE-MS I and CAMMS03409 Investigators September 3, 2017

Objective:

To evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting MS (RRMS) (CARE-MS I; NCT00530348).

Methods:

Alemtuzumab-treated patients received treatment courses at baseline and 12 months later; after the core study, they could enter an extension (NCT00930553) with as-needed alemtuzumab retreatment for relapse or MRI activity.… Read More...

Wang, J. Z., Vyas, M. V., Saposnik, G., Burneo, J. G. September 3, 2017

Objective:

We conducted a meta-analysis of the incidence of early and late seizures following ischemic stroke as well as a systematic review of their pharmacologic treatment.

Methods:

Observational studies that reported incidence of seizures following ischemic stroke and those that reported treatment response to any particular antiepileptic drugs (AEDs) were included.… Read More...

Andoird App
Loading...